Biochem/physiol Actions

Primary Targetvitamin D receptor

General description

Active hormonal form of vitamin D, formed by the renal 1-hydroxylation of 25-(OH)D₃. Has immunomodulatory properties in vitro and in vivo. Prevents the development of clinical diabetes in NOD mice, which are an animal model of human autoimmune diabetes. Induces reversible hydrolysis of the sphingomyelin cycle and generates ceramide. Stimulates intestinal Ca²⁺ and phosphate transport and mobilizes Ca²⁺ from bone. Involved in cellular differentiation, carcinogenesis, and insulin secretion.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Semizarov, D., et al. 1998. Proc. Natl. Acad. Sci. USA95, 15412.Hannun, Y.A. 1994. J. Biol. Chem.269, 3125.Mathieu, C., et al. 1994. Diabetologica37, 552.Thomasset, M. 1994. Pathol. Biol.42, 163.Horton, W.E., Jr., et al. 1991. J. Biol. Chem.266, 24804.Larsen, C.G., et al. 1991. Biochem. Biophys. Res. Commun.176, 1020.Thavarajah, M., et al. 1991. Biochem. Biophys. Res. Commun.176, 1189.Wakasugi, M., et al. 1991. Prostaglandins42, 127.Matsumoto, K., et al. 1990. Biochem. Biophys. Res. Commun.166, 916.Simpson, R.U., et al. 1989. J. Biol. Chem.264, 19710.DeLuca, H.F., and Schnoes, H.K. 1983. Annu. Rev. Biochem.52, 411.

Packaging

Packaged under inert gas

Physical form

A 1 mM (50 ug/112 µL) solution of Vitamin D3, 1α, 25-Dihydroxy- (Cat. No. 679101) in DMSO.

Reconstitution

Following initial thaw, aliquot and freeze (-20°C). Aliquots are stable for up to 6 months at -20°C.

Warning

Toxicity: Standard Handling (A)